Nutr Res Pract.  2021 Feb;15(1):26-37. 10.4162/nrp.2021.15.1.26.

Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats

Affiliations
  • 1Department of Nutrition, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
  • 2Department of Nutrition, School of Public Health in Sun Yat-sen University, Guangzhou 510080, China

Abstract

BACKGROUND/OBJECTIVES
Hyperuricemic nephropathy is a common cause of acute kidney injury. Resveratrol can ameliorate kidney injury, but the explicit mechanism remains unclear. We investigated the effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats.
MATERIALS/METHODS
A rat model of hyperuricemic nephropathy was established by the oral administration of a mixture of adenine and potassium oxinate. Biochemical analysis and hematoxylin and eosin staining were performed to assess the rat kidney function. Enzymelinked immunosorbent assays were performed to evaluate the immune and oxidative responses.
RESULTS
The expression levels of urine albumin and β2-microglobulin were significantly decreased after resveratrol treatment. In addition, the levels of serum creatinine and uric acid were significantly decreased in the resveratrol groups, compared with the control group.The levels of proinflammatory factors, such as interleukin-1β and tumor necrosis factor-α, in kidney tissue and serum were also increased in the hyperuricemic rats, and resveratrol treatment inhibited their expression. Moreover, the total antioxidant capacity in kidney tissue as well as the superoxide dismutase and xanthine oxidase levels in serum were all decreased by resveratrol treatment.
CONCLUSIONS
Resveratrol may protect against hyperuricemic nephropathy through regulating the inflammatory response.

Keyword

Hyperuricemia; resveratrol; kidney diseases; inflammation; anti-oxidative effect

Figure

  • Fig. 1 The serum uric acid level in the hyperuricemia group after treatment with different dosages of resveratrol. (A) Adenine (100 mg/kg/day) and potassium oxinate (1,000 mg/kg/day) or vehicle were orally administered every morning. Low-dose (25 mg/kg/day), medium-dose (50 mg/kg/day), and high-dose (100 mg/kg/day) RES were administered every afternoon. (B) The serum levels of uric acid from the control or hyperuricemic rats treated without or with different concentrations of RES were measured. Samples were collected at 7, 14, and 21 days after treatment. Data are expressed as the mean ± SEM (n = 8).RES, resveratrol; SEM, standard error of the mean; BUN, blood urea nitrogen.*P < 0.05, **P < 0.01 compared with the hyperuricemia group.

  • Fig. 2 The body weight and kidney indices of the hyperuricemic rats were measured after treatment with resveratrol. (A) The body weight and (B) kidney indices of the control or hyperuricemic rats treated without or with different concentrations of RES were measured at 0, 7, 14, and 21 days after treatment. Data are presented as the mean ± SEM (n = 8).RES, resveratrol; SEM, standard error of the mean.**P < 0.01 compared with the hyperuricemia group.

  • Fig. 3 The different doses of RES were administered every afternoon. (A) Serum urea nitrogen and (B) creatinine were measured to assess the renal function. Data are presented as the mean ± SEM (n = 8).RES, resveratrol; SEM, standard error of the mean.*P < 0.05, **P < 0.01 compared with the hyperuricemia group.

  • Fig. 4 The levels of (A) urine protein contents, (B) microalbumin, and (C) β2-microglobulin in urine from the control or hyperuricemic rats treated without or with different concentrations of RES were measured. Data are presented as the mean ± SEM (n = 8).RES, resveratrol; SEM, standard error of the mean.*P < 0.05, **P < 0.01 compared with the hyperuricemia group.

  • Fig. 5 RES ameliorates renal morphological changes and reduces the infiltration of inflammatory cells in the kidney. Representative photographs of H&E-stained rat renal sections at a magnification of 200×. The groups were as follows: control group, hyperuricemia group (sham), hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. The blue arrows represent eosinophilic insoluble proteins; the black arrow represents salt crystals; and the green arrow represents edema of renal tubular epithelial cells.RES, resveratrol; H&E, hematoxylin and eosin.

  • Fig. 6 RES preserves rat renal function and reduces cytokine production induced by hyperuricemia. The concentrations of (A) MDA, (B) SOD, (C) TAOC, (D) IL-1β, (E) IL-6, and (F) TNF-α in kidney tissue were measured by ELISA. The groups were as follows: control group, hyperuricemia group, hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. Data are presented as the mean ± SEM (n = 8).MDA, malondialdehyde; SOD, superoxide dismutase; TAOC, total antioxidant capacity; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; ELISA, enzyme-linked immunosorbent assay; RES, resveratrol.*P < 0.05, **P < 0.01 compared with the hyperuricemia group.

  • Fig. 7 The levels of (A) SOD, (B) TAOC, (C) XOD, (D) IL-1β, (E) IL-6, and (F) TNF-α in serum were measured by ELISA. The groups were as follows: control group, hyperuricemia group, hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. Data are presented as the mean ± SEM (n = 8).SOD, superoxide dismutase; TAOC, total antioxidant capacity; XOD, xanthine oxidase; IL, interleukin; TNF, tumor necrosis factor; ELISA, enzyme-linked immunosorbent assay; RES, resveratrol.*P < 0.05, **P < 0.01 compared with the hyperuricemia group.


Reference

1. Adedeji AO, Pourmohamad T, Chen Y, Burkey J, Betts CJ, Bickerton SJ, Sonee M, McDuffie JE. Investigating the value of urine volume, creatinine, and cystatin C for urinary biomarkers normalization for drug development studies. Int J Toxicol. 2019; 38:12–22. PMID: 30673360.
Article
2. Fidan C, Kantar A, Baskın E, Gülleroğlu K, Akdur A, Moray G, Haberal M. Effects of hyperuricemia on renal function in pediatric renal transplant recipients. Exp Clin Transplant. 2015; 13 Suppl 1:247–250.
3. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep. 2002; 4:270–274. PMID: 12010614.
Article
4. Lim AY, Teng GG. Allopurinol: a necessary evil. Singapore Med J. 2009; 50:925–926. PMID: 19787189.
5. Zhang W, Chen H, Sun C, Wu B, Bai B, Liu H, Shan X, Liang G, Zhang Y. A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration. Mol Med Rep. 2019; 19:4770–4778. PMID: 31059027.
Article
6. Pan QR, Ren YL, Zhu JJ, Hu YJ, Zheng JS, Fan H, Xu Y, Wang G, Liu WX. Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet. Nutrients. 2014; 6:2619–2631. PMID: 25025298.
Article
7. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev. 2013; 2013:568093. PMID: 24379901.
Article
8. Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, Li Z, Kong LD. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol Nutr Food Res. 2012; 56:1433–1444. PMID: 22865646.
Article
9. Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes. 2011; 60:634–643. PMID: 21270273.
Article
10. Chen YH, Fu YC, Wu MJ. Does resveratrol play a role in decreasing the inflammation associated with contrast induced nephropathy in rat model? J Clin Med. 2019; 8:147.
Article
11. Wu M, Gu J, Mei S, Xu D, Jing Y, Yao Q, Chen M, Yang M, Chen S, Yang B, Qi N, Hu H, Wüthrich RP, Mei C. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrol Dial Transplant. 2016; 31:1826–1834. PMID: 27190325.
Article
12. Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother. 2020; 125:109767. PMID: 32058210.
Article
13. Den Hartogh DJ, Tsiani E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies. Nutrients. 2019; 11:11.
14. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5:493–506. PMID: 16732220.
15. Zhu W, Pang M, Dong L, Huang X, Wang S, Zhou L. Anti-inflammatory and immunomodulatory effects of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats. Life Sci. 2012; 91:369–376. PMID: 22910180.
16. Chen L, Yang S, Zumbrun EE, Guan H, Nagarkatti PS, Nagarkatti M. Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages. Mol Nutr Food Res. 2015; 59:853–864. PMID: 25643926.
Article
17. Luo CJ, Luo F, Bu QD, Jiang W, Zhang W, Liu XM, Che L, Luan H, Zhang H, Ma RX, Sun JP, Xu Y. Protective effects of resveratrol on acute kidney injury in rats with sepsis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164:49–56. PMID: 30994109.
Article
18. Wang N, Mao L, Yang L, Zou J, Liu K, Liu M, Zhang H, Xiao X, Wang K. Resveratrol protects against early polymicrobial sepsis-induced acute kidney injury through inhibiting endoplasmic reticulum stress-activated NF-κB pathway. Oncotarget. 2017; 8:36449–36461. PMID: 28430592.
Article
19. Gan Y, Tao S, Cao D, Xie H, Zeng Q. Protection of resveratrol on acute kidney injury in septic rats. Hum Exp Toxicol. 2017; 36:1015–1022. PMID: 27837177.
Article
20. Wang Y, Feng F, Liu M, Xue J, Huang H. Resveratrol ameliorates sepsis-induced acute kidney injury in a pediatric rat model via Nrf2 signaling pathway. Exp Ther Med. 2018; 16:3233–3240. PMID: 30214546.
Article
21. Bekpinar S, Karaca E, Yamakoğlu S, Alp-Yıldırım FI, Olgac V, Uydes-Doğan BS, Cibali E, Gultepe S, Uysal M. Resveratrol ameliorates the cyclosporine-induced vascular and renal impairments: possible impact of the modulation of renin-angiotensin system. Can J Physiol Pharmacol. 2019; 97:1115–1123. PMID: 31613143.
Article
22. Xue HY, Yuan L, Cao YJ, Fan YP, Chen XL, Huang XZ. Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Biosci Rep. 2016; 36:e00339. PMID: 27129290.
Article
23. Smith NC, Christian SL, Taylor RG, Santander J, Rise ML. Immune modulatory properties of 6-gingerol and resveratrol in Atlantic salmon macrophages. Mol Immunol. 2018; 95:10–19. PMID: 29367081.
Article
24. Erkasap S, Erkasap N, Bradford B, Mamedova L, Uysal O, Ozkurt M, Ozyurt R, Kutlay O, Bayram B. The effect of leptin and resveratrol on JAK/STAT pathways and Sirt-1 gene expression in the renal tissue of ischemia/reperfusion induced rats. Bratisl Lek Listy (Tlacene Vyd). 2017; 118:443–448.
Article
25. Li J, Li L, Wang S, Zhang C, Zheng L, Jia Y, Xu M, Zhu T, Zhang Y, Rong R. Resveratrol alleviates inflammatory responses and oxidative stress in rat kidney ischemia-reperfusion injury and H2O2-Induced NRK-52E Cells via the Nrf2/TLR4/NF-κB Pathway. Cell Physiol Biochem. 2018; 45:1677–1689. PMID: 29490296.
26. Bienholz A, Mae Pang R, Guberina H, Rauen U, Witzke O, Wilde B, Petrat F, Feldkamp T, Kribben A. Resveratrol does not protect from ischemia-induced acute kidney injury in an in vivo rat model. Kidney Blood Press Res. 2017; 42:1090–1103. PMID: 29207388.
27. He T, Guan X, Wang S, Xiao T, Yang K, Xu X, Wang J, Zhao J. Resveratrol prevents high glucose-induced epithelial-mesenchymal transition in renal tubular epithelial cells by inhibiting NADPH oxidase/ROS/ERK pathway. Mol Cell Endocrinol. 2015; 402:13–20. PMID: 25540919.
Article
28. Wang Y, Wang B, Qi X, Zhang X, Ren K. Resveratrol protects against post-contrast acute kidney injury in rabbits with diabetic nephropathy. Front Pharmacol. 2019; 10:833. PMID: 31402864.
Article
29. Ramalingam A, Santhanathas T, Shaukat Ali S, Zainalabidin S. Resveratrol supplementation protects against nicotine-induced kidney injury. Int J Environ Res Public Health. 2019; 16:16.
Article
30. Hall S, Dixit M, Arany I. Resveratrol attenuates nicotine-mediated oxidative injury by inducing manganese superoxide dismutase in renal proximal tubule cells. In Vivo. 2017; 31:551–555. PMID: 28652419.
31. Soussi D, Danion J, Baulier E, Favreau F, Sauvageon Y, Bossard V, Matillon X, Turpin F, Belgsir EM, Thuillier R, Hauet T. Vectisol formulation enhances solubility of resveratrol and brings its benefits to kidney transplantation in a preclinical porcine model. Int J Mol Sci. 2019; 20:2268.
Article
32. Ibrahim A, Al-Hizab FA, Abushouk AI, Abdel-Daim MM. Nephroprotective effects of benzyl isothiocyanate and resveratrol against cisplatin-induced oxidative stress and inflammation. Front Pharmacol. 2018; 9:1268. PMID: 30524274.
Article
33. Cigremis Y, Akgoz M, Ozen H, Karaman M, Kart A, Gecer M, Atalan G. Resveratrol ameliorates cisplatin-induced oxidative injury in New Zealand rabbits. Can J Physiol Pharmacol. 2015; 93:727–735. PMID: 26243022.
Article
34. Denek Z, Erbil G, Ozbal S, Micili SC, Ozogul C. The effects of resveratrol against trifluralin toxicity in the urinary tract of rats. Toxicol Ind Health. 2016; 32:106–117. PMID: 24021433.
Article
35. Al Dera HS. Protective effect of resveratrol against aluminum chloride induced nephrotoxicity in rats. Saudi Med J. 2016; 37:369–378. PMID: 27052279.
Full Text Links
  • NRP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr